Skip to main content
. 2017 Jan 27;10:551–557. doi: 10.2147/OTT.S97584

Figure 2.

Figure 2

(A) PFS curves of the same group of patients after treatment with 90Y-Dotatoc and after retreatment with low-dose 177Lu-Dotatate. (B) OS curve for retreatment group.

Note: It was not possible to elaborate a posttreatment OS curve as all of the patients included in the study were originally treated in different centers in Italy.

Abbreviations: PFS, progression-free survival; OS, overall survival; 90Y-Dotatoc, 90Y-DOTA-Tyr3-octreotide; 177Lu-Dotatate, 177Lu-DOTA-Tyr3-octreotate.